Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the critical care of liver and pediatric diseases.  The company is now advancing its lead candidate, VS-01, into a Phase 2a trial which will lead to pivotal trials in two orphan indications.

Products, services, technology

VS-01 is a proprietary first-line treatment for acute liver diseases able to simultaneously support the failing liver, brain, and kidneys. VS-01 received  orphan drug (FDA, EMA) and Rare Pediatric Disease designations (FDA) which help to streamline and value its clinical development pathway.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2015

  • Number of employees in Switzerland

    1-9

Key business